CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
Want to see HK:1228 full AI Analyst Report?
1228 Stock Chart & Stats
HK$2.52
<HK$0.01(5.93%)
At close: 4:00 PM EST
HK$2.52
<HK$0.01(5.93%)
Day’s Range― - ―
52-Week RangeHK$0.14 - HK$3.50
Previous CloseN/A
Volume661.00K
Average Volume (3M)5.03M
Market Cap
HK$1.19B
Enterprise ValueHK$694.38M
Total Cash (Recent Filing)HK$1.96M
Total Debt (Recent Filing)HK$34.97M
Price to Earnings (P/E)54.7
Beta1.17
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding595,443,360
10 Day Avg. Volume2,153,700
30 Day Avg. Volume5,027,972
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)-3.32
Price to Sales (P/S)22.72
P/FCF Ratio-29.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)HK$299.65M
Bulls Say, Bears Say
Bulls Say
Specialty / Rare-disease FocusA focused rare-disease and specialty-medicine strategy creates durable demand and higher barriers to entry, supporting premium pricing, long product lifecycles, and partnership opportunities. This niche orientation underpins sustained commercial and licensing potential over months.
Relatively Strong Gross MarginsSustained gross margins in the 60–70% range imply that, once scale and SG&A are controlled, the company can convert revenue to operating leverage. Strong product-level margins support durability of returns from commercialized therapies and royalties over the medium term.
Lower Debt / De-risking Of Capital StructureA meaningful reduction in absolute debt lowers refinancing and interest burden risks, improving near-term financial flexibility. For a cash-burning biotech, lower leverage reduces tail risk and makes future financing or partnering less urgent over the coming months.
Bears Say
Negative Shareholders' EquityPersistently negative equity reflects cumulative losses and weak capital buffers, restricting access to some financing channels and increasing governance and creditor scrutiny. This fragile capital structure materially limits long-term financial flexibility.
Persistent Cash BurnRepeated negative operating and free cash flow indicates the business cannot self-finance operations or R&D. Ongoing cash burn raises the probability of dilution or debt raising, making sustained investment and commercialization dependent on external funding.
Revenue Volatility And Recent ContractionSharp, volatile revenue declines undermine scale economics and leave fixed R&D and SG&A costs uncovered, prolonging negative EBIT. Without stable top-line recovery, profitability and cash-generation improvements are uncertain over the medium term.
CANbridge Pharmaceuticals Inc. News
1228 FAQ
What was CANbridge Pharmaceuticals Inc.’s price range in the past 12 months?
CANbridge Pharmaceuticals Inc. lowest stock price was HK$0.14 and its highest was HK$3.50 in the past 12 months.
What is CANbridge Pharmaceuticals Inc.’s market cap?
CANbridge Pharmaceuticals Inc.’s market cap is HK$1.19B.
When is CANbridge Pharmaceuticals Inc.’s upcoming earnings report date?
CANbridge Pharmaceuticals Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 88 days.
How were CANbridge Pharmaceuticals Inc.’s earnings last quarter?
CANbridge Pharmaceuticals Inc. released its earnings results on Mar 30, 2026. The company reported -HK$0.095 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.095.
Is CANbridge Pharmaceuticals Inc. overvalued?
According to Wall Street analysts CANbridge Pharmaceuticals Inc.’s price is currently Overvalued.
Does CANbridge Pharmaceuticals Inc. pay dividends?
CANbridge Pharmaceuticals Inc. does not currently pay dividends.
What is CANbridge Pharmaceuticals Inc.’s EPS estimate?
CANbridge Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CANbridge Pharmaceuticals Inc. have?
CANbridge Pharmaceuticals Inc. has 595,443,360 shares outstanding.
What happened to CANbridge Pharmaceuticals Inc.’s price movement after its last earnings report?
CANbridge Pharmaceuticals Inc. reported an EPS of -HK$0.095 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.382%.
Which hedge fund is a major shareholder of CANbridge Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in HK:1228
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CANbridge Pharmaceuticals Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
696.29%
12-Months-Change
Fundamentals
Return on Equity
9.41%
Trailing 12-Months
Asset Growth
48.19%
Trailing 12-Months
Company Description
CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---